Cost of drug development: Difference between revisions
CSV import |
CSV import |
||
| Line 2: | Line 2: | ||
{{stb}} | {{stb}} | ||
{{short-articles-ni}} | {{short-articles-ni}} | ||
{{No image}} | |||
Latest revision as of 10:44, 10 February 2025
The cost of drug development is the full cost of bringing a new drug (i.e., new chemical entity) to market from drug discovery through clinical trials to approval. Typically, companies spend tens to hundreds of millions of U.S. dollars on drug development. One element of the complexity is that the much-publicized final numbers often not only include the out-of-pocket expenses for conducting a series of Phase I-III clinical trials, but also the capital costs of the long period (10 or more years) during which the company must cover out-of-pocket costs for preclinical drug discovery. Additionally, companies often do not report whether a given figure includes the capitalized cost or comprises only out-of-pocket expenses, or both
| This article is a stub. You can help WikiMD by registering to expand it. |